Over-expression of YKL-40 in 76N MECs decreases E-cad and β-casein, but increases MMP-9 expression and cell invasiveness. by Steve Scully (202724)

data & R code_20250504.zip<b>Plant invasion decreases the likelihood of community persistence </b><b>through asymmetric competition</b> by Chengjin Chu (19476862)

Clinical evolution at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

SaFi, laboratory, radiology, vaccine status, and inpatient treatment data. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Relationship between a simplified SCOPE score at start of treatment with anakinra and clinical outcome at 60 days. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Adverse pregnancy outcomes recorded among study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Probability of medical discharge at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Quality of Antenatal care and adverse maternal and fetal outcomes. by Seth Amponsah-Tabi (13949142)

Subjects:

Distribution of different levels of quality of antenatal care provided to study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Sociodemographic and reproductive factors associated with good quality antenatal care. by Seth Amponsah-Tabi (13949142)

Subjects:

Sociodemographic and reproductive characteristics of the study participants. by Seth Amponsah-Tabi (13949142)

Subjects:

Clinical outcome at 60 days based on SaFi, anakinra and a simplified SCOPE. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Comorbidities and severity scales at admission for the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

S1 Data - by Seth Amponsah-Tabi (13949142)

Subjects:

Probability of remaining as an inpatient at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Probability of medical discharge at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

Probability of remaining as an inpatient at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

A simplified SCOPE score. by Ismael Francisco Aomar-Millán (14838595)

Subjects:

A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy by Eric M. Davis (1733638)

“…After PAB, mice spent significantly more time in NREM sleep compared to the control group over a 24 hour period (53.5 ± 1.5% vs. 46.6 ± 1.4%; p < 0.01) and exhibited an inability to both cycle into REM sleep and decrease delta density across the light/sleep period. …”

Sequences of the qPCR primers used. by Lucas H. Oronel (8525697)

“…In addition, Tolvaptan effectively inhibited the V2 receptor in both control and CKD rats, decreasing AQP2 expression and increasing diuresis. …”